NASDAQ:CLRB - Cellectar Biosciences Stock Price, News & Analysis

$2.18
+0.06 (+2.83 %)
(As of 08/16/2019 04:00 PM ET)
Today's Range
$2.11
Now: $2.18
$2.20
50-Day Range
$2.05
MA: $2.15
$2.24
52-Week Range
$1.22
Now: $2.18
$4.28
Volume55,800 shs
Average Volume80,410 shs
Market Capitalization$20.49 million
P/E RatioN/A
Dividend YieldN/A
Beta1.17
Cellectar Biosciences, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131, which is in Phase II clinical study in patients with relapsed or refractory (R/R) multiple myeloma (MM) and a range of B-cell malignancies, as well as in Phase I clinical study for R/R MM. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLRB
CUSIPN/A
Phone608-441-8120

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.58 per share

Profitability

Net Income$-13,240,000.00

Miscellaneous

Employees7
Market Cap$20.49 million
Next Earnings Date11/12/2019 (Estimated)
OptionableNot Optionable

Receive CLRB News and Ratings via Email

Sign-up to receive the latest news and ratings for CLRB and its competitors with MarketBeat's FREE daily newsletter.


Cellectar Biosciences (NASDAQ:CLRB) Frequently Asked Questions

What is Cellectar Biosciences' stock symbol?

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

When did Cellectar Biosciences' stock split? How did Cellectar Biosciences' stock split work?

Shares of Cellectar Biosciences reverse split on Tuesday, July 17th 2018. The 1-10 reverse split was announced on Friday, July 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 13th 2018. An investor that had 100 shares of Cellectar Biosciences stock prior to the reverse split would have 10 shares after the split.

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences Inc (NASDAQ:CLRB) posted its earnings results on Monday, August, 12th. The biopharmaceutical company reported ($0.46) EPS for the quarter, beating analysts' consensus estimates of ($0.70) by $0.24. View Cellectar Biosciences' Earnings History.

When is Cellectar Biosciences' next earnings date?

Cellectar Biosciences is scheduled to release their next quarterly earnings announcement on Tuesday, November 12th 2019. View Earnings Estimates for Cellectar Biosciences.

What price target have analysts set for CLRB?

2 equities research analysts have issued 1 year price targets for Cellectar Biosciences' shares. Their forecasts range from $4.00 to $6.00. On average, they expect Cellectar Biosciences' share price to reach $5.00 in the next year. This suggests a possible upside of 129.4% from the stock's current price. View Analyst Price Targets for Cellectar Biosciences.

What is the consensus analysts' recommendation for Cellectar Biosciences?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellectar Biosciences.

Has Cellectar Biosciences been receiving favorable news coverage?

Headlines about CLRB stock have been trending negative recently, according to InfoTrie. The research group scores the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cellectar Biosciences earned a media sentiment score of -2.3 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Cellectar Biosciences.

Are investors shorting Cellectar Biosciences?

Cellectar Biosciences saw a decline in short interest in the month of July. As of July 31st, there was short interest totalling 403,300 shares, a decline of 5.3% from the June 30th total of 425,700 shares. Based on an average trading volume of 461,000 shares, the short-interest ratio is presently 0.9 days. Approximately 8.7% of the company's stock are sold short. View Cellectar Biosciences' Current Options Chain.

Who are some of Cellectar Biosciences' key competitors?

What other stocks do shareholders of Cellectar Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Encana (ECA), Bombardier, Inc. Class B (BBD.B), Bonavista Energy (BNP) and Hudbay Minerals (HBM).

Who are Cellectar Biosciences' key executives?

Cellectar Biosciences' management team includes the folowing people:
  • Mr. James V. Caruso, Pres, CEO & Director (Age 60)
  • Mr. Jarrod Longcor, Chief Bus. Officer (Age 46)
  • Mr. Charles T. Bernhardt, Interim Chief Financial Officer (Age 58)
  • Gregory J. Lynch, Sec.

Who are Cellectar Biosciences' major shareholders?

Cellectar Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Boxer Capital LLC (9.79%), Tang Capital Management LLC (7.24%), CVI Holdings LLC (1.13%) and Morgan Stanley (0.38%). Company insiders that own Cellectar Biosciences stock include James V Caruso, Jarrod Longcor, John Neis and Stephen A Hill. View Institutional Ownership Trends for Cellectar Biosciences.

Which institutional investors are selling Cellectar Biosciences stock?

CLRB stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley. View Insider Buying and Selling for Cellectar Biosciences.

Which institutional investors are buying Cellectar Biosciences stock?

CLRB stock was bought by a variety of institutional investors in the last quarter, including Boxer Capital LLC, Tang Capital Management LLC and CVI Holdings LLC. Company insiders that have bought Cellectar Biosciences stock in the last two years include James V Caruso and Jarrod Longcor. View Insider Buying and Selling for Cellectar Biosciences.

How do I buy shares of Cellectar Biosciences?

Shares of CLRB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cellectar Biosciences' stock price today?

One share of CLRB stock can currently be purchased for approximately $2.18.

How big of a company is Cellectar Biosciences?

Cellectar Biosciences has a market capitalization of $20.49 million. The biopharmaceutical company earns $-13,240,000.00 in net income (profit) each year or ($4.66) on an earnings per share basis. Cellectar Biosciences employs 7 workers across the globe.View Additional Information About Cellectar Biosciences.

What is Cellectar Biosciences' official website?

The official website for Cellectar Biosciences is http://www.cellectar.com/.

How can I contact Cellectar Biosciences?

Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The biopharmaceutical company can be reached via phone at 608-441-8120 or via email at [email protected]


MarketBeat Community Rating for Cellectar Biosciences (NASDAQ CLRB)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  164 (Vote Outperform)
Underperform Votes:  140 (Vote Underperform)
Total Votes:  304
MarketBeat's community ratings are surveys of what our community members think about Cellectar Biosciences and other stocks. Vote "Outperform" if you believe CLRB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CLRB will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 8/17/2019 by MarketBeat.com Staff

Featured Article: What is an SEC Filing?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel